5 results about "Factor ii" patented technology

This invention discloses a method for preparing filler particles for targeted adsorption of low-density lipoprotein (LDL) in patients with atherosclerosis. The steps include: 1) washing D101 macroporous resin with ultrapure water and physiological saline; 2) adding fibrin and PBS solution for soaking; adding thrombin factor II; adding zinc gluconate during the reaction; 3) repeating step 2) at least three times and drying the D101 macroporous resin; 4) adding physiological saline and D101 macroporous resin to lyophilized protein ApoB100 and mixing thoroughly; 5) lyophilizing the resin obtained in step 4) while controlling the humidity at 65±5% to obtain the finished product. This application utilizes this adhesion effect to target the adsorption of foam cells in atherosclerosis, adsorbing foam cells through hemoperfusion, removing redundant blood lipid components in the body, reducing macrophage infiltration of organs and blood vessels, and reducing pathological changes in organs and blood vessels.

The invention discloses a traditional Chinese medicine composition for relieving itching. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 6-50g of radix scutellariae, 6-50g of fructus gardeniae, 6-50g of fructus forsythiae, 6-50g of flos lonicerae and 6-50g of radix geutianae. According to the invention, the radix scutellariae for inhibiting histamine release, the fructus forsythiae for antagonizing histamine receptors and the felwort for blocking itching signal transduction are subjected to multi-way action to cover the whole link of itching-inducing medium generation-receptor combination-signal transmission, so that rapid itching relieving is realized; the cape jasmine for promoting prothrombin activation, the baical skullcap root for enhancing platelet aggregation and the honeysuckle flower for contracting blood vessels act together, so that the blood coagulation time is shortened, and the effect fluctuation of a single hemostasis mechanism is avoided; the five medicines jointly inhibit the release of inflammatory factors, enhance the local antibacterial ability, relieve inflammatory pruritus, prevent wound infection, avoid vicious circle of itching-grasping-infection-aggravated itching, and reduce the infection risk after bleeding.

A method and kit are provided for measuring and monitoring a combined effect of an anticoagulant drug on coagulation factors II and X in a patient taking the anticoagulant drug. The method includes adding one or more coagulation reagents with the factor VII to a test sample and determining blood clotability of the test sample by measuring an influence of factors II and X.

The present disclosure provides antibodies that bind to the catalytic domain of factor XI (FXI) and methods of use thereof. According to certain embodiments, the antibodies are antagonistic antibodies that inhibit clot formation via the intrinsic pathway without affecting hemostasis, as demonstrated by their ability to prolong aPTT without affecting PT. Thus, these antagonistic antibodies can be used in the treatment or therapeutic regimen of blood clotting diseases or disorders that have clot formation as a risk factor, such as, but not limited to, atrial fibrillation. In certain embodiments, the present disclosure includes antibodies that bind to FXI and mediate clot or thrombus formation. The antibodies of the present disclosure can be fully human, non-naturally occurring antibodies.

A method and kit are provided for measuring and monitoring a combined effect of an anticoagulant drug on coagulation factors II and X in a patient taking the anticoagulant drug. The method includes adding one or more coagulation reagents with the factor VII to a test sample and determining blood clotability of the test sample by measuring an influence of factors II and X.